BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 16461021)

  • 1. Is there a role for immunotherapy in hepatocellular carcinoma?
    Zerbini A; Pilli M; Ferrari C; Missale G
    Dig Liver Dis; 2006 Apr; 38(4):221-5. PubMed ID: 16461021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunobiology and gene-based immunotherapy of hepatocellular carcinoma.
    Geissler M; Mohr L; Ali MY; Grimm CF; Ritter M; Blum HE
    Z Gastroenterol; 2003 Nov; 41(11):1101-10. PubMed ID: 14648380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-mediated immune responses to alpha-fetoprotein and other antigens in hepatocellular carcinoma.
    Behboudi S; Boswell S; Williams R
    Liver Int; 2010 Apr; 30(4):521-6. PubMed ID: 20040052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor effects of immunotherapeutic peptide on the treatment of hepatocellular carcinoma with HBc carrier.
    Kong J; Diao Z; Deng X; Zhong H; Yao W; Hu X
    Oncol Rep; 2007 Jul; 18(1):279-85. PubMed ID: 17549380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy of hepatocellular carcinoma with a vaccine based on xenogeneic homologous alpha fetoprotein in mice.
    Zhang W; Liu J; Wu Y; Xiao F; Wang Y; Wang R; Yang H; Wang G; Yang J; Deng H; Li J; Wen Y; Wei Y
    Biochem Biophys Res Commun; 2008 Nov; 376(1):10-4. PubMed ID: 18725206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma.
    Vollmer CM; Eilber FC; Butterfield LH; Ribas A; Dissette VB; Koh A; Montejo LD; Lee MC; Andrews KJ; McBride WH; Glaspy JA; Economou JS
    Cancer Res; 1999 Jul; 59(13):3064-7. PubMed ID: 10397245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas.
    Bouet-Toussaint F; Cabillic F; Toutirais O; Le Gallo M; Thomas de la Pintière C; Daniel P; Genetet N; Meunier B; Dupont-Bierre E; Boudjema K; Catros V
    Cancer Immunol Immunother; 2008 Apr; 57(4):531-9. PubMed ID: 17764010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivery of mengovirus-derived RNA replicons into tumoural liver enhances the anti-tumour efficacy of a peripheral peptide-based vaccine.
    Couty JP; Crain AM; Gerbaud S; Labasque M; Marchiol C; Fradelizi D; Boudaly S; Guettier C; Vignuzzi M; van der Werf S; Escriou N; Viguier M
    Cancer Immunol Immunother; 2008 Aug; 57(8):1161-71. PubMed ID: 18256833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-derived dendritic cells transduced with an a-fetoprotein-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells.
    González-Carmona MA; Märten A; Hoffmann P; Schneider C; Sievers E; Schmidt-Wolf IG; Sauerbruch T; Caselmann WH
    Liver Int; 2006 Apr; 26(3):369-79. PubMed ID: 16584401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
    Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
    Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential of immunotherapy for hepatocellular carcinoma.
    Breous E; Thimme R
    J Hepatol; 2011 Apr; 54(4):830-4. PubMed ID: 21145836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma.
    Hui D; Qiang L; Jian W; Ti Z; Da-Lu K
    Dig Liver Dis; 2009 Jan; 41(1):36-41. PubMed ID: 18818130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene therapy by membrane-expressed superantigen for alpha-fetoprotein-producing hepatocellular carcinoma.
    Si S; Sun Y; Li Z; Ge W; Zhang X; Hu P; Huang Y; Chen G; Song H; Huang Y; Ma B; Li X; Sui Y
    Gene Ther; 2006 Nov; 13(22):1603-10. PubMed ID: 16855617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications.
    Fatourou EM; Koskinas JS
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1499-510. PubMed ID: 19828011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cell as therapeutic vaccines against tumors and its role in therapy for hepatocellular carcinoma.
    Sun K; Wang L; Zhang Y
    Cell Mol Immunol; 2006 Jun; 3(3):197-203. PubMed ID: 16893500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer.
    Butterfield LH; Ribas A; Potter DM; Economou JS
    Cancer Immunol Immunother; 2007 Dec; 56(12):1931-43. PubMed ID: 17522860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of hepatocellular carcinoma: is there a place for regulatory T-lymphocyte depletion?
    Cany J; Tran L; Gauttier V; Judor JP; Vassaux G; Ferry N; Conchon S
    Immunotherapy; 2011 Apr; 3(4 Suppl):32-4. PubMed ID: 21524167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapeutic strategies for hepatocellular carcinoma.
    Butterfield LH
    Gastroenterology; 2004 Nov; 127(5 Suppl 1):S232-41. PubMed ID: 15508089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics and surgical outcome in hepatocellular carcinoma without hepatitis B virus surface antigen or hepatitis C virus antibody.
    Tanaka K; Shimada H; Matsuo K; Nagano Y; Endo I; Togo S
    Ann Surg Oncol; 2007 Mar; 14(3):1170-81. PubMed ID: 17195904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular immune responses to hepatocellular carcinoma: lessons for immunotherapy.
    Schmidt N; Neumann-Haefelin C; Thimme R
    Dig Dis; 2012; 30(5):483-91. PubMed ID: 23108304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.